Disease relevance of Breast Neoplasms, Male

• BRCA2 germline mutations in male breast cancer cases and breast cancer families [1].
• We have examined 22 families with at least one case of male breast cancer for linkage to the hereditary breast and ovarian cancer locus, BRCA1, on chromosome 17q [2].
• Head trauma and exposure to prolactin-elevating drugs as risk factors for male breast cancer [3].
• A case of brain metastases from male breast cancer responding to tamoxifen [4].
• The significance of HER-2/neu overexpression in ductal carcinoma in situ and the HER-2/neu status in uncommon female breast conditions and male breast cancer are also considered [5].

High impact information on Breast Neoplasms, Male

• However, this variant is present in 5.1% of individuals with breast cancer from 718 families that do not carry mutations in BRCA1 or BRCA2 (P = 0.00000003), including 13.5% of individuals from families with male breast cancer (P = 0.00015) [6].
• Male breast cancer and the androgen receptor gene [7].
• Tamoxifen and male breast cancer [8].
• Letter: Familial male breast cancer [9].
• The remaining eight cases (89%) of male breast cancer with a family history of breast/ovarian cancer in first-degree relatives remain unaccounted for by mutations in either the BRCA1 gene or the BRCA2 gene [10].

Chemical compound and disease context of Breast Neoplasms, Male

• As such, BRCA2 can exert its tumor suppressor function, in part, by modulating androgen signaling, which has been shown to be antiproliferative in a subset of breast cancer cells and particularly implicated in male breast tumors [11].
• Cytoplasmic estrogen receptors were detected in 12 of 13 male breast cancer tumors [12].
• Clinical correlations of steroid receptors and male breast cancer [13].
• Cytoplasmic and nuclear estrogen and progesterone receptors in male breast cancer [12].
• Response to megestrol in male breast carcinoma [14].

Biological context of Breast Neoplasms, Male

• Six of the eight families with male breast cancer revealed frameshift mutations, two in BRCA1 and four in BRCA2 [15].
• Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival [16].
• We analyzed a series of 27 archival samples from male breast cancer patients for BRCA2 mutations and loss of heterozygosity at BRCA2 locus [17].
• In the present study, we performed a genome-wide survey by comparative genomic hybridization (CGH) of somatic genetic aberrations in 26 male breast cancers, including five tumors from BRCA2 mutation carriers [18].
• We did not find a significant association between male breast cancer risk and CYP17 genotypes [19].

Anatomical context of Breast Neoplasms, Male

• High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history [20].
• Increased aromatase expression in the stromal cells is considered to contribute to the increment in the in situ estrogen concentration and the development of male breast carcinoma [21].
• We report, for the first time, a high frequency of LOH at chromosome 13q12-13 in sporadic male breast cancer and its association with factors indicating a poor prognosis for this tumor (e.g., lymph node metastasis and negative progesterone receptor status) [22].
• In addition, the loss of the Y chromosome in the tumors but not in peripheral blood lymphocytes, suggests a possible role for this abnormality in the pathogenesis of male breast carcinoma [23].
• Two deaths from male breast cancer (SMR = 14.36) and three from cancer of endocrine glands were found (SMR = 3.44) [24].

Gene context of Breast Neoplasms, Male

• Many BRCA2-linked families also contain cases of male breast cancer [1].
• BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients [25].
• We cannot exclude the fact that a small fraction of hereditary, family-positive male breast cancers could be attributable to CHEK2 mutations [26].
• Frequent amplification and overexpression of CCND1 in male breast cancer [27].
• Estrogen receptors (ER) were present in tumor specimens from 29 of 34 cases of male breast cancer [13].

Analytical, diagnostic and therapeutic context of Breast Neoplasms, Male

• Presence of 72 kDa glycoprotein MBTAA in MF1 and specificity of the anti-MBTAA antibodies in the sera of male breast cancer patients were further confirmed by Western blot analysis [28].
• This case-control study from the South East of Scotland shows that a polymorphism of the CYP17 gene is associated with an increased risk of male breast cancer [29].
• Tamoxifen response following no response to orchiectomy in metastatic male breast cancer: a case report [30].
• By immunohistochemistry, we found nuclear, perinuclear, endoplasmic reticulum, Golgi vesicle, secretion and apical cytoplasmic stainings in gynecomastias and sporadic and hereditary male breast cancers, for BRCA1 and BRCA2 protein expressions [31].
• A case of advanced male breast cancer successfully treated by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy combined with tamoxifen [32].

References